Điều trị bằng polysulfate pentosan cải thiện chức năng vận động với mức tăng của phân tử bám dính tế bào nội mô hòa tan -1 trong bệnh lý thần kinh liên quan đến HTLV-1

Ando H, Sato T, Tomaru U, Yoshida M, Utsunomiya A, Yamauchi J, Araya N, Yagishita N, Coler-Reilly A, Shimizu Y, Yudoh K, Hasegawa Y, Nishioka K, Nakajima T, Jacobson S, Yamano Y (2013) Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136:2876–2887 Araya N, Takahashi K, Sato T, Nakamura T, Sawa C, Hasegawa D, Ando H, Aratani S, Yagishita N, Fujii R, Oka H, Nishioka K, Nakajima T, Mori N, Yamano Y (2011) Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease. Antivir Ther 16:89–98 Aye MM, Matsuoka E, Moritoyo T, Umehara F, Suehara M, Hokezu Y, Yamanaka H, Isashiki Y, Osame M, Izumo S (2000) Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol 100:245–252 Best I, Adaui V, Verdonck K, González E, Tipismana M, Clark D, Gotuzzo E, Vanham G (2006) Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 146:226–233 Bohannon RW, Smith MB (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206–207 Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF (1997) Increases in soluble VCAM- I correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-I b. Ann Neurol 41:669–674 de-Thé G, Bomford R (1993) An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 9:381–386 Fukushima N, Nakamura T, Nishiura Y, Ida H, Aramaki T, Eguchi K (2008) HTLV-I production based on activation of integrin/ligand signaling in HTLV-I-infected T cell lines derived from HAM/TSP patients. Intervirology 51:1234–1239 Ghosh P (1999) The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 28:211–267 Guerreiro JB, Santos SB, Morgan DJ, Porto AF, Muniz AL, Ho JL, Teixeira AL Jr, Teixeira MM, Carvalho EM (2006) Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol 145:296–301 Hollsberg P, Hafler DA (1993) Pathogenesis of diseases induced by human T-lymphotropic virus type I infection. N Engl J Med 328:1173–1182 Ida H, Kurata A, Eguchi K, Yamashita I, Nakashima M, Sakai M, Kawabe Y, Nakamura T, Nagataki S (1994) Mechanism of inhibitory effect of dextran sulfate and heparin on human T-cell lymphotropic virus type I (HTLV-I)-induced syncytium formation in vitro: role of cell to cell contact. Antiviral Res 23:143–159 Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR (2003) Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299:1713–1716 Ijichi S, Izumo S, Eiraku N, Machigashira K, Kubota R, Nagai M, Ikegami N, Kashio N, Umehara F, Maruyama I, Osame M (1993) An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med Hypotheses 41:542–547 Irony-Tur-Sinai M, Vlodavsky I, Ben-Sasson SA, Pinto F, Sicsic C, Brenner T (2003) A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation. J Neurol Sci 206:49–57 Izumo S, Usuku K, Osame M, Machigashira K, Johnosono M, Nakagawa M (1989) The neuropathology of HLV-I-associated myelopathy in Japan: report of an autopsy case and review of the literature. In: Román GC, Vernant J-C, Osame M (eds) HTLV-I and the nervous system. Alan R, Liss, Inc, New York, pp 261–267 Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW (2005) Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol 79:12692–12702 Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, Rieckmann P (2000) Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 123:687–697 Kumagai K, Shirabe S, Miyata N, Murata M, Yamauchi A, Kataoka Y, Niwa M (2010) Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis—an open clinical trial. BMC Clin Pharma 10:7 Matsuda M, Tsukada N, Miyagi K, Yanagisawa N (1995) Increased levels of soluble vascular cell adhesion molecule-l (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 59:35–40 Nagasato K, Nakamura T, Ichinose K, Nishiura Y, Ohishi K, Shibayama K, Watanabe H, Tsujihata M, Nagataki S (1993) Heparin treatment in patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy. J Neurol Sci 115:161–168 Nakamura T, Nishiura Y, Eguchi K (2009) Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Cent Nerv Syst Agents Med Chem 9:137–149 Nakamura T (2009) HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol 47:182–194 Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi K (2009) Disulfide-mediated apoptosis of human T-lymphotropic virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther 14:533–542 Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, Tara M, Igata A (1987) Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann Neurol 21:117–122 Osame M, Igata A, Matsumoto M (1989) HTLV-I-associated myelopathy (HAM) revisited. In: Román GC, Vernant J-C, Osame M (eds) HTLV-I and the nervous system. Alan R, Liss, Inc, New York, pp 213–223 Osame M (1990) Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA (ed) Human retrovirology: HTLV. Raven, New York, pp 191–197 Tsukada N, Miyagi K, Matsuda M, Yanagisawa N (1993) Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. Ann Neurol 33:646–649 Umehara F, Izumo S, Takeya M, Takahashi K, Sato E, Osame M (1996) Expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy. Acta Neuropathol 91:343–350 Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S (1995) Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 69:2863–2868 Weiner HL, Hafler DA (1988) Immunotherapy of multiple sclerosis. Ann Neurol 23:211–222 Yoshida A, Piroozmand A, Sakurai A, Fujita M, Uchiyama T, Kimura T, Hayashi Y, Kiso Y, Adachi A (2005) Establishment of a biological assay system for human retroviral protease activity. Microbes Infect 7:820–824